source
- Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidateNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist. The candidate,…
- UniQure’s gene therapy still slows Huntington’s disease after four years, but benefit declinesUniQure reported that its one‑time gene therapy, AMT‑130, continues to decelerate the progression of Huntington’s disease four years after being surgically delivered into patients' brains. A new a…